Zydus Lifesciences Limited announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2025, showcasing strong growth across all major business segments.
For the second quarter of FY26, Zydus reported revenue from operations of Rs.61,232 million, marking a 17% year-on-year increase. EBITDA rose sharply by 38% to Rs.20,158 million, while the EBITDA margin improved by 500 basis points to 32.9%. Net profit for the quarter surged 38% to Rs.12,586 million. The company invested Rs.4,820 million in research and development, accounting for 7.9% of revenues.
During the first half of FY26, Zydus achieved revenue of Rs.1,26,969 million, up 11% year-on-year, with EBITDA of Rs. 41,043 million and net profit of Rs.27,254 million, representing growth of 16% and 17% respectively. The company maintained a healthy balance sheet with a net debt-to-equity ratio of 0.09x and net debt-to-EBITDA of 0.3x as of September 30, 2025.
The India formulations business generated Rs.15,931 million in Q2, up 8% year-on-year, supported by growth in innovative and specialty products. Zydus also launched VaxiFlu™, India’s first trivalent influenza vaccine aligned with WHO recommendations.
The consumer wellness division recorded an impressive 31% growth, with revenue reaching Rs.6,374 million. The company completed its first international wellness acquisition by taking over the UK-based Comfort Click Limited (CCL), enhancing its global footprint in the digital consumer healthcare and nutrition space.
US formulations contributed Rs.27,437 million, up 14% from the previous year, supported by new product launches and regulatory milestones. Zydus introduced seven new products and filed six ANDAs during the quarter. It also received its first Notice of Compliance from Health Canada for Varenicline tablets.
International formulations business witnessed strong growth of 39% year-on-year, contributing Rs.7,513 million, driven by performance in emerging markets and Europe. The newly expanded MedTech segment delivered Rs.1,532 million in revenue following the complete acquisition of Amplitude Surgical. API revenues rose 23% to Rs. 1,472 million.
Zydus received Establishment Inspection Reports (EIRs) from the USFDA with positive outcomes—Voluntary Action Indicated (VAI) for its Ahmedabad and Baddi facilities, and No Action Indicated (NAI) for its SEZ II unit.
In its innovation pipeline, Zydus reported positive Phase 2(b)/3 clinical trial results for Saroglitazar Magnesium in treating Primary Biliary Cholangitis (PBC) and plans to file a New Drug Application with the USFDA in Q4 FY26. The company also received approval to begin Phase II trials of its Bivalent Typhoid Conjugate Vaccine in India.
Managing Director Dr. Sharvil Patel highlighted that the company’s performance reflects the strength of its diversified business model and strategic focus on innovation and global expansion. He emphasized Zydus’s continued commitment to quality, compliance, and patient-centric growth.
